Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | GCK | P35557 | 17/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.46 |
| ▸ | RECQL | P46063 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1146877 | 0.92 | GCK (0.54) | NPC1RAB9AGCKKCNH2 | |
| SCHEMBL13891597 | 0.89 | GCK (0.63) | NPC1HPGDRAB9ASMN1; SMN2GCK | |
| SCHEMBL1147142 | 0.89 | GCK (0.63) | NPC1HPGDRAB9ASMN1; SMN2GCK | |
| SCHEMBL1147200 | 0.86 | GCK (0.57) | NPC1HPGDRAB9ASMN1; SMN2GCK | |
| SCHEMBL2658987 | 0.83 | GCK (0.63) | GCKKCNH2 | |
| SCHEMBL1146875 | 0.81 | GCK (0.67) | GCKKCNH2 | |
| SCHEMBL13891595 | 0.81 | GCK (0.67) | GCKKCNH2 | |
| SCHEMBL1147088 | 0.78 | GCK (0.62) | NPC1RAB9AGCKKCNH2 | |
| SCHEMBL1146886 | 0.76 | GCK (0.80) | GCKKCNH2 | |
| SCHEMBL1146946 | 0.76 | GCK (0.69) | GCKKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110034432-A1 | BENZAMIDE DERIVATIVES AND THEIR USE AS GLUCOKINASE ACTIVATING AGENTS | ASTRAZENECA AB (SE) | 2011-02-10 | — | — | US | claimed |
| EP-1718624-B1 | BENZAMIDE DERIVATIVES AND THEIR USE AS GLUCOKINASE ACTIVATING AGENTS | ASTRAZENECA AB (SE) | 2009-03-25 | — | — | EP | claimed |
| US-20080280872-A1 | Benzamide Derivatives and Their Use as Glucokinase Activating Agents | ASTRAZENECA AB (SE) | 2008-11-13 | — | — | US | claimed |
| US-20110034432-A1 | BENZAMIDE DERIVATIVES AND THEIR USE AS GLUCOKINASE ACTIVATING AGENTS | ASTRAZENECA AB (SE) | 2011-02-10 | — | — | US | disclosed |
| EP-2048137-A1 | Benzamide derivatives and their use as glucokinase activating agents. | AstraZeneca AB (SE) | 2009-04-15 | — | — | EP | disclosed |
| EP-1718624-B1 | BENZAMIDE DERIVATIVES AND THEIR USE AS GLUCOKINASE ACTIVATING AGENTS | ASTRAZENECA AB (SE) | 2009-03-25 | — | — | EP | disclosed |
| US-20080280872-A1 | Benzamide Derivatives and Their Use as Glucokinase Activating Agents | ASTRAZENECA AB (SE) | 2008-11-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110034432-A1 | BENZAMIDE DERIVATIVES AND THEIR USE AS GLUCOKINASE ACTIVATING AGENTS | GCK, GCKR, GRK4 | NPC1 3123/4885HPGD 899/4885RAB9A 3933/4885 |
| US-20080280872-A1 | Benzamide Derivatives and Their Use as Glucokinase Activating Agents | GCK, GCKR, GRK4 | NPC1 3123/4885HPGD 899/4885RAB9A 3933/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.